BMS has entered into an agreement to acquire Orbital Therapeutics for $1,5 billion. The Cambridge-based company is developing a new generation of RNA medicines that reprogram the immune system directly in the body. The focus is on the preclinical candidate OTX-201, which uses optimized circular RNA encoding a CD19-targeted CAR, delivered via targeted lipid nanoparticles, to induce CAR expression in vivo and deplete autoreactive B cells.